Search research articles
Contact Us
Filters
Showing results (131-140 of 206) with videos related to
Page
of 21
Sort By:
Cells
|
January 10, 2025
Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients
Phillip Schiele, Stefan Kolling, Stanislav Rosnev, et al.
Molecular Cancer Therapeutics
|
July 25, 2015
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer
Sebastian Stintzing, Wu Zhang, Volker Heinemann, et al.
European Radiology
|
June 9, 2018
CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial
Matthias F Froelich, Volker Heinemann, Wieland H Sommer, et al.
Scientific Reports
|
April 14, 2026
Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer models
Florian Doelvers, Katharina Wansch, Anna Kuehn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 24, 2022
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials
Jingyuan Wang, Yi Xiao, Fotios Loupakis, et al.
BMC Cancer
|
August 25, 2011
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, et al.
Cancer Medicine
|
December 30, 2025
Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study
Katharina Wansch, François Schneider, Florian Dölvers, et al.
International Journal of Cancer
|
April 4, 2017
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial
Marta Schirripa, Wu Zhang, Volker Heinemann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 8, 2022
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)
Arndt Stahler, Dominik P Modest, Ludwig Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 30, 2025
The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pancreatic cancer patients
François Schneider, Haotian Chen, Uwe Pelzer, et al.
Page
of 21
Search research articles
Search
Showing results (131-140 of 206) with videos related to
Sort By:
Page
of 21
Cells
|
January 10, 2025
Flow Cytometric Assessment of FcγRIIIa-V158F Polymorphisms and NK Cell Mediated ADCC Revealed Reduced NK Cell Functionality in Colorectal Cancer Patients
Phillip Schiele, Stefan Kolling, Stanislav Rosnev, et al.
Molecular Cancer Therapeutics
|
July 25, 2015
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer
Sebastian Stintzing, Wu Zhang, Volker Heinemann, et al.
European Radiology
|
June 9, 2018
CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial
Matthias F Froelich, Volker Heinemann, Wieland H Sommer, et al.
Scientific Reports
|
April 14, 2026
Impact of culture dimensionality and matrix composition on morphology, phenotype and drug response in pancreatic cancer models
Florian Doelvers, Katharina Wansch, Anna Kuehn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 24, 2022
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials
Jingyuan Wang, Yi Xiao, Fotios Loupakis, et al.
BMC Cancer
|
August 25, 2011
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, et al.
Cancer Medicine
|
December 30, 2025
Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study
Katharina Wansch, François Schneider, Florian Dölvers, et al.
International Journal of Cancer
|
April 4, 2017
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial
Marta Schirripa, Wu Zhang, Volker Heinemann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 8, 2022
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)
Arndt Stahler, Dominik P Modest, Ludwig Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 30, 2025
The basis for future personalized therapy approaches - Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pancreatic cancer patients
François Schneider, Haotian Chen, Uwe Pelzer, et al.
Page
of 21